Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025
- Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
- Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
- Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
- Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data